Inactive Instrument

PCAS Stock

PCA

FR0000053514

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

24-02-09	Orapi: takeover bid reopens on February 12
24-02-02	Orapi: 3.15 million shares tendered to the takeover bid
23-12-22	Orapi: takeover bid opens on December 27
23-12-18	PCAS: 200 ME capital increase
23-11-03	PCAS: OPAS to start this Friday
23-10-24	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
23-10-16	Progyny, Inc. : Want to have a baby?
23-09-07	PCAS: Seqens launches minority share offer
23-09-05	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-07-27	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
23-05-31	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
23-05-25	PCAS: sale of Canadian subsidiary confirmed
23-05-25	PCAS to Divest Canadian Arm to Japan's DIC	MT

23-10-24	PCAS: Net Sales as of September 30, 2023	GL
23-09-06	PCAS: RESULTS AS OF JUNE 30, 2023	GL
23-07-27	Pcas: Net sales as of June 30, 2023	GL
23-05-25	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
23-05-02	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

24-02-09	Orapi : l'OPA réouvre le 12 février
24-02-02	Orapi : 3,15 millions d'actions apportées à l'OPA
24-01-05	Progyny, Inc.: ¿Quieres tener un bebé?
23-12-22	Orapi : l'OPA démarre le 27 décembre
23-12-18	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	2025-05-02
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	1999-02-28

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	2014-02-28
Janine Cossy BRD	Director/Board Member	-	-

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news: PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	+3.49%	+10.04%	+58.68%	+119.56%	1,144B
JOHNSON & JOHNSON	+2.19%	+4.32%	+33.88%	+69.52%	625B
ABBVIE INC.	+2.26%	+5.37%	+24.57%	+97.69%	511B
ROCHE HOLDING AG	+2.58%	+8.37%	+38.71%	+63.14%	377B
MERCK & CO., INC.	+3.25%	+4.45%	+71.80%	+44.44%	366B
NOVARTIS AG	+1.85%	+6.04%	+21.47%	+49.17%	291B
ASTRAZENECA PLC	+1.76%	+6.07%	+0.43%	+20.98%	262B
AMGEN INC.	+3.29%	+6.32%	+44.71%	+57.43%	237B
GILEAD SCIENCES, INC.	+2.25%	+5.81%	+27.13%	+101.17%	194B
Average	+1.84%	+4.19%	+35.71%	+69.23%	445.32B
Weighted average by Cap.	+1.43%	+4.68%	+40.92%	+80.67%